Philogen postpones in Milan
Philogen, the Italian biotech company that had been planning a Milan IPO, called off the deal before books were due to close on Friday after Bayer, a development partner, cast doubt on the future of a collaboration agreement, a material change that left the bookrunners unwilling to continue with the listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts